Skip to main
BIO
BIO logo

Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

Bio-Rad Laboratories (BIO) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Rad Laboratories is positioned to grow its revenue and earnings at a faster rate than its peers due to expected improvements in end-markets, which could lead to multiple expansions. The company is also set to benefit from ongoing ERP efficiencies that are anticipated to enhance margins, alongside the expected stabilization and growth of its ddPCR and process chromatography segments. With a current valuation of approximately 7x EBITDA and less than 1.5x sales, Bio-Rad presents an attractive entry point for investors as market pressures are expected to subside and growth trends normalize.

Bears say

Bio-Rad Laboratories faces significant risks that contribute to a negative outlook on its stock, primarily stemming from potentially overstated revenue and earnings estimates due to declining demand for its products. The company continues to experience elevated inventories and reduced equipment sales as a result of ongoing supply chain disruptions that were exacerbated during the pandemic. Furthermore, Bio-Rad's exposure to macroeconomic variables, including foreign currency fluctuations and corporate governance risks associated with its majority shareholders, may further complicate its financial trajectory and limit share price growth.

Bio-Rad Laboratories (BIO) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Rad Laboratories (BIO) Forecast

Analysts have given Bio-Rad Laboratories (BIO) a Buy based on their latest research and market trends.

According to 12 analysts, Bio-Rad Laboratories (BIO) has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $323.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $323.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Rad Laboratories (BIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.